Clinical Trials

Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for $1,500,000 over 2 years to support the modification of their proprietary Total Holographic Characterization®...

Viking Therapeutics, Inc , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK5211 in patients who...

Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. These results greatly strengthen the company's previously accumulated data...

Boston Biomedical Inc,  announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ (gastroesophageal junction) cancer will be unblinded. This decision is based on...

OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for cancer immunotherapy. Submission of the Company's second Investigational New Drug ("IND") application is expected by the third quarter of 2018. OATD-02...

goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced its partnership with Citeline, part of Informa's Pharma Intelligence vertical, to integrate data from Citeline's intelligence platforms — including Trialtrove and Sitetrove — with goBalto's Select....

Astellas Pharma Inc and Pfizer Inc announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC)....